These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Matrix metalloproteinase inhibitors: applications in oncology. Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405 [TBL] [Abstract][Full Text] [Related]
4. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Overall CM; Kleifeld O Nat Rev Cancer; 2006 Mar; 6(3):227-39. PubMed ID: 16498445 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Rudek MA; Venitz J; Figg WD Pharmacotherapy; 2002 Jun; 22(6):705-20. PubMed ID: 12066962 [TBL] [Abstract][Full Text] [Related]
6. Role of matrix metalloproteinases and their inhibitors in pancreatic cancer. Evans JD; Ghaneh P; Kawesha A; Neoptolemos JP Digestion; 1997; 58(6):520-8. PubMed ID: 9438596 [TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Vihinen P; Kähäri VM Int J Cancer; 2002 May; 99(2):157-66. PubMed ID: 11979428 [TBL] [Abstract][Full Text] [Related]
9. Progress in the development of matrix metalloproteinase inhibitors. Tu G; Xu W; Huang H; Li S Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616 [TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7. Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131 [TBL] [Abstract][Full Text] [Related]
12. Clinical studies with matrix metalloproteinase inhibitors. Brown PD APMIS; 1999 Jan; 107(1):174-80. PubMed ID: 10190295 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases as therapeutic targets in cancer. Vihinen P; Ala-aho R; Kähäri VM Curr Cancer Drug Targets; 2005 May; 5(3):203-20. PubMed ID: 15892620 [TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase inhibitors as anticancer agents. Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645 [TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. Jabłońska-Trypuć A; Matejczyk M; Rosochacki S J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase inhibitors. Brown PD Breast Cancer Res Treat; 1998; 52(1-3):125-36. PubMed ID: 10066077 [TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Kähäri VM; Saarialho-Kere U Ann Med; 1999 Feb; 31(1):34-45. PubMed ID: 10219712 [TBL] [Abstract][Full Text] [Related]
18. Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2. Yu AE; Hewitt RE; Kleiner DE; Stetler-Stevenson WG Biochem Cell Biol; 1996; 74(6):823-31. PubMed ID: 9164651 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Duffy MJ; McCarthy K Int J Oncol; 1998 Jun; 12(6):1343-8. PubMed ID: 9592197 [TBL] [Abstract][Full Text] [Related]
20. Extracellular matrix remodelling: the role of matrix metalloproteinases. Stamenkovic I J Pathol; 2003 Jul; 200(4):448-64. PubMed ID: 12845612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]